Are Peptides Legal in Oregon? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Oregon as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Oregon attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Oregon statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Oregon has scheduled or banned on its own. The Oregon Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Oregon's licensing boards have also spoken to peptide prescribing by clinics and medspas, which is where state-level risk actually sits (details below). Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Oregon at a glance

State controlled-substances law: ORS Chapter 475 (Controlled Substances), ORS 475.005 and 475.035; schedules adopted by the State Board of Pharmacy in OAR 855-080 (oregon.public.law)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (OAR 855-080-0023 (Schedule III incorporates 21 CFR 1308.13)) (oregon.public.law)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: The Board of Pharmacy's Semaglutide Position Statement (adopted 6 February 2025) says compounding is barred where the product is an essential copy of a commercially available drug; that a prescription showing only a patient name and formulation does not invoke the patient-specific exception and lower price is never a justification; that only semaglutide base is a component of an approved drug, semaglutide is not on the 503A bulks list and no salt form may be used; that active ingredient must be pharmaceutical grade with a certificate of analysis from an FDA-registered establishment; and that research-use-only products may not be used for compounding in any circumstance (2025-02-06) (oregon.gov)
Medical board on peptide prescribing: The Oregon Medical Board's prescribing topics page carries the Board of Pharmacy's GLP-1 language (compounded versions sold online are not FDA approved; active ingredient must be pharmaceutical grade from an FDA-registered source) and relays the FDA's recommendation that consumers not buy unapproved products containing the investigational peptide retatrutide. No statement on BPC-157, research peptides generally or peptide clinics (2025) (oregon.gov)
GLP-1 by telehealth: Yes. The Oregon Medical Board's Statement of Philosophy on Telemedicine (last amended 4 April 2024) applies the same standard of care as in-person care and states that treatment based solely on an online questionnaire without individualised review and assessment does not constitute an acceptable standard of care; there is no in-person examination mandate for non-controlled drugs such as GLP-1s. (oregon.gov)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence high

The federal rules that apply in Oregon, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Oregon:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Oregon. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Oregon law adds

Oregon's controlled-substances law (ORS Chapter 475 (Controlled Substances), ORS 475.005 and 475.035; schedules adopted by the State Board of Pharmacy in OAR 855-080) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (oregon.public.law)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Oregon's schedules or in a Oregon-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Oregon incorporates the federal Schedule III by reference, and the federal schedule does not list human growth hormone, somatropin or chorionic gonadotropin, so HGH is not a controlled substance in Oregon; it remains a prescription drug restricted by the federal HGH statute. (OAR 855-080-0023 (Schedule III incorporates 21 CFR 1308.13)) (oregon.public.law)

Compounded semaglutide and tirzepatide

2025-02-06. The Board of Pharmacy's Semaglutide Position Statement (adopted 6 February 2025) says compounding is barred where the product is an essential copy of a commercially available drug; that a prescription showing only a patient name and formulation does not invoke the patient-specific exception and lower price is never a justification; that only semaglutide base is a component of an approved drug, semaglutide is not on the 503A bulks list and no salt form may be used; that active ingredient must be pharmaceutical grade with a certificate of analysis from an FDA-registered establishment; and that research-use-only products may not be used for compounding in any circumstance. (oregon.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

2025. The Oregon Medical Board's prescribing topics page carries the Board of Pharmacy's GLP-1 language (compounded versions sold online are not FDA approved; active ingredient must be pharmaceutical grade from an FDA-registered source) and relays the FDA's recommendation that consumers not buy unapproved products containing the investigational peptide retatrutide. No statement on BPC-157, research peptides generally or peptide clinics. (oregon.gov)

Buying, possessing and using research peptides in Oregon

ORS 475.752(3) makes it unlawful to knowingly possess a controlled substance without a valid prescription, so possessing an unscheduled research peptide is not a state offence; the compounding and research-use-only restrictions in the Board's position statement bind pharmacies and sellers, not individual buyers. (oregon.public.law)

Ordering from a vendor in another state. Almost every research-peptide order into Oregon is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. The Oregon Medical Board's Statement of Philosophy on Telemedicine (last amended 4 April 2024) applies the same standard of care as in-person care and states that treatment based solely on an online questionnaire without individualised review and assessment does not constitute an acceptable standard of care; there is no in-person examination mandate for non-controlled drugs such as GLP-1s. (oregon.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Oregon law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Oregon

2025-02-19. Oregon's attorney general is on the signatory list of the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. No Oregon attorney general or board action against a specific peptide seller or medspa was found.

Frequently asked questions

Is BPC-157 legal in Oregon?

Oregon has not scheduled BPC-157, so possessing it is not a Oregon offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Oregon?

Yes. The Oregon Medical Board's Statement of Philosophy on Telemedicine (last amended 4 April 2024) applies the same standard of care as in-person care and states that treatment based solely on an online questionnaire without individualised review and assessment does not constitute an acceptable standard of care; there is no in-person examination mandate for non-controlled drugs such as GLP-1s. The Oregon Board of Pharmacy position on compounded versions: The Board of Pharmacy's Semaglutide Position Statement (adopted 6 February 2025) says compounding is barred where the product is an essential copy of a commercially available drug; that a prescription showing only a patient name and formulation does not invoke the patient-specific exception and lower price is never a justification; that only semaglutide base is a component of an approved drug, semaglutide is not on the 503A bulks list and no salt form may be used; that active ingredient must be pharmaceutical grade with a certificate of analysis from an FDA-registered establishment; and that research-use-only products may not be used for compounding in any circumstance.

Is HGH legal in Oregon?

Only with a valid prescription for an approved use. Oregon does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Oregon fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.